CLIMB is a US based, randomized, double-blind, placebo-controlled Phase 2 study to evaluate the safety, tolerability and efficacy of ARINA-1 in participants with bronchiectasis. Efficacy endpoints in this trial include quality of life, sputum rheological markers, blood inflammatory markers and other exploratory clinical markers.

“We are pleased to report that we have completed adult patient enrollment in the CLIMB study for bronchiectasis. This is a great milestone for our company and for people living with bronchiectasis,” said Dan Copeland, Chief Executive Officer of Renovion. “CLIMB will provide data regarding ARINA-1 as a first line therapy for bronchiectasis, a serious pulmonary disease that today has no approved treatments. The enthusiasm of the treating community and patient interest in the trial reflect the significant need for a therapy that can help these patients reduce symptoms and improve quality of life. We see ARINA-1 as a potential first line therapy to address the significant impact of bronchiectasis symptoms in the lives of patients, and we look forward to sharing the trial results later this quarter.”

The CLIMB study was conducted at 10 sites in the United States. Renovion is developing ARINA-1 to break the cycle of mucus, inflammation and infection in chronic inflammatory lung diseases by delivering ARINA-1 directly to the lungs of patients. Based on experience in patients to date, ARINA-1 is well positioned to be a first line therapy for patients that need a fast onset of action and an attractive safety profile.

About Renovion

Renovion is a clinical-stage pharmaceutical company focused on developing ARINA-1, novel nebulized therapy delivered to the lungs to treat pulmonary diseases. ARINA-1 clears mucus and reduces damaging inflammation in the airways to restore lung health. Renovion is also conducting clinical trials for ARINA-1 for BOS in lung transplant patients in an ongoing Phase 3 trial and also in patients with chronic bronchitis. The Renovion team has in-depth experience in drug development with extensive scientific expertise in chronic pulmonary conditions and inflammation. For more information about Renovion, visit https://www.renovion.com/ or follow Renovion on Twitter (@RenovionInc).

About Bronchiectasis

Non-CF bronchiectasis (NCFBE) is a chronic pulmonary disorder characterized by a vicious cycle of mucus, inflammation, and infection that results in permanently dilated airways. Individuals with NCFBE experience significant and life-altering mucus symptoms and chronic cough. Stagnant mucus often traps bacteria and leads to frequent exacerbations and increased shortness of breath, which often leads to clinical decline. Bronchiectasis affects approximately 340,000 to 520,000 patients in the U.S. There are currently no FDA-approved therapies for bronchiectasis in the US, Europe or Japan.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240111664650/en/